Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effectiveness of Zoladex® 10.8 mg Compared to Zoladex® 3.6mg in the Treatment of Premenopausal and Perimenopausal Hormone Receptor Positive Breast Cancer: A Real-World Study

NCT05184257 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05184257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05184257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effectiveness of Zoladex® 10.8 mg Compared to Zoladex® 3.6mg in the Treatment of Premenopausal and Perimenopausal Hormone Receptor Positive Breast Cancer: A Real-World Study
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 6, 2022
Completion date
December 15, 2023
Enrollment
1,176 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer